Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA Hypomethylation Predisposes to Type II Diabetes

By LabMedica International staff writers
Posted on 12 Jan 2012
A novel genomic screening technique that was used to compare DNA methylation variations between a group of individuals with type II diabetes and a group of normal individuals detected specific regions of hypomethylation in the DNA of the diabetes group.

Investigators at the Hebrew University of Jerusalem (Israel) designed a stepwise study to search for disease-contributing DNA methylation variations. More...
First, a pool based, genome-scale screen was carried out among 1169 type II diabetes cases and control individuals. Next, in-depth analyses were performed at selected top-ranking regions.

Results published in the January 15, 2012, online edition of the journal Human Molecular Genetics revealed an excess of differentially methylated sites in genomic regions that were previously associated with type II diabetes through genetic studies. A clear-cut region of hypomethylation was identified in the DNA of the type II diabetes cases relative to controls. The effect was independent of the sequence polymorphism in the region and persisted among individuals carrying the sequence-risk alleles. The odds of belonging to the type II diabetes group were increased by 6.1% for every 1% decrease in methylation.

A prospective study carried out in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to type II diabetes, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators.

The data uncovered by this study showed that, “Low methylation levels at the analyzed sites were an early marker of type II diabetes and pointed to a novel mechanism by which early-onset, interindividual methylation variation at isolated nonpromoter genomic sites predisposes to type II diabetes.”

Related Links:

Hebrew University of Jerusalem




Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.